Hollister Biosciences Announces Third Quarter Fiscal 2021 Financial Results Including Revenue of USD $14.5M and Adjusted Ebitda of USD $1.2M Psychedelics Investing
iX Biopharma Signs Exclusive License Agreement For Wafermine And Other Sublingual Ketamine Wafer Products Psychedelics Investing
BetterLife Successfully Completes Phase 1 and Initiates Phase 2 Clinical Trials with Interferon Alpha-2b in COVID-19 Patients in Chile Pharmaceutical Investing
Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans Pharmaceutical Investing
Numinus Receives Conditional Approval to Graduate to the Toronto Stock Exchange Pharmaceutical Investing
Stocks2Watch's Virtual Investor Luncheon Agenda Updated for Tuesday November 30 Psychedelics Investing
Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine Psychedelics Investing
Seelos Therapeutics Raises $20 Million in Private Placement of Senior Secured Convertible Note Psychedelics Investing
Hollister Biosciences Inc. Announces Results of Its 2021 Annual General and Special Shareholder Meeting Psychedelics Investing
Love Pharma Signs Letter of Intent to Acquire 100% Interest in MicrDoz Therapy Inc. To Expedite Pilot Study of Psilocybin Assisted Treatment of Cannabis Use Disorder with World Leading University Pharmaceutical Investing
